• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Aptabio to initiate Phase II oral Covid-19 therapy trial pharmaceutical-technology
    March 29, 2021
    South Korean company Aptabio is all set to initiate a Phase II trial of its oral therapy, APX-115, for treating Covid-19.A transmembrane enzyme NADPH oxidase (NOX) inhibitor, APX-115 was studied in Europe for treating patients with diabetes complications.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service